Delivery Order SPE2DB22D3016-SPE2DB25FBGX9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,033.95 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. The contract, awarded on August 11, 2025, is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $18,837.70 delivery order on August 19, 2025, for the supply of Remicade 100 mg vials, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,603.96 on July 29, 2025, for the supply of Remicade 100 mg vials, with a completion date of July 30, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was awarded through open competition. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $17,733.06 from the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Remicade 100 mg vials. The contract is competitively awarded with no set-aside designation and carries a firm fixed price structure with an ultimate completion date of August 26, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $23,484.87 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials, with an ultimate completion date of August 12, 2025. This firm fixed price contract, awarded on August 11, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $50,458.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials, with an ultimate completion date of August 21, 2025. This is a non-set-aside competitive award issued on August 20, 2025, with performance to be conducted at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order under its...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $38,665.68 by the Defense Logistics Agency on August 27, 2025, for the supply of Remicade 100 mg vials. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The product will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 28, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,366.24 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. The contract, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed price pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Remicade 100 mg vials, a TNF-alpha inhibitor immunosuppressant used primarily for rheumatologic and gastrointestinal conditions. This firm fixed-price contract, valued at $12,877.18, represents a competitively awarded non-set-aside procurement with performance scheduled for completion by August 26, 2025, and will be fulfilled from the vendor's corporate office location in...
- The Defense Logistics Agency awarded Amerisourcebergen Drug Corporation a $6,250.50 firm fixed price delivery order contract to supply 4561696173 units of Remicade 100 mg vials. The single day contract has a period of performance from August 3 to August 4, 2023, with all work taking place in Conshohocken, Pennsylvania. As the Defense Logistics Agency is responsible for procuring pharmaceuticals and medical supplies for the U.S. Department of Defense, this delivery order was likely placed to...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBGX9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,032.89 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. The contract, awarded September 2, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery at its corporate office location in Conshohocken, PA 19428. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Remicade, a biologic immunosuppressant medication used in treating autoimmune conditions, represents part of the company's extensive portfolio of specialty medications and medical commodities delivered through the DLA's Medical Supply Chain to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 9/2/25 |